Skip to content

R&D at other companies

Staar Surgical logo
Staar SurgicalSTAA
$9.93M-12.5%
Bausch + Lomb logo
Bausch + LombBLCO
$101M+17.4%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$4.52M+33.8%
Schering-Plough logo
Schering-PloughSGP
$8.54M+41.1%
IAR
Integra LifeSciencesIART
$23.5M-5.0%
ITG
Integer HoldingsITGR
$16.24M+14.4%

Other financials

Income statement

See full
Revenue$13.4M-5.2%
Gross profit$6.4M-10.4%
Operating income$2.2M+139%
Net income$36.3M+233%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$12.5M-36.1%
Total debt$7.6M+206%
Total equity$10.8M+149%
Total assets$66.2M-9.2%

Cash flow

See full
Operating cash flow-$4.3M+38.4%
CapEx$77.0K-31.9%
Free cash flow-

Valuation

See full
Market cap$70.13M-53.1%
Enterprise value$65.21M-54.9%
P/E2.4×
P/S1.2×-1.3×

Profitability

See full
Gross margin45.7%-2.1pp
Operating margin-28.7%+7.3pp
Net margin50.9%+30.7pp
FCF margin-26.6%

Returns & leverage

See full
Return on equity-164%-235pp
Debt / equity0.7×
Current ratio2.4×+0.6×

Where this comes from

Reported directly by LENSAR, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: LENSAR, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about LENSAR, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LENSAR, Inc.'s R&D?
LENSAR, Inc. (LNSR) reported R&D of $1.39M in Q1 2026.
How has LENSAR, Inc.'s R&D changed year-over-year?
LENSAR, Inc.'s R&D decreased by 9.7% year-over-year, from $1.53M to $1.39M.
What is the long-term trend for LENSAR, Inc.'s R&D?
Over 4 years (2021 to 2025), LENSAR, Inc.'s R&D has grown at a -17.9% compound annual growth rate (CAGR), from $12.36M to $5.62M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.